Schmidt R A, Jonas U, Oleson K A, Janknegt R A, Hassouna M M, Siegel S W, van Kerrebroeck P E
University of Colorado Health Science Center, Denver 80262, USA.
J Urol. 1999 Aug;162(2):352-7.
A prospective, randomized study was performed to evaluate sacral nerve stimulation for the treatment of refractory urinary urge incontinence.
Primary outcome variables were obtained from voiding diaries. After baseline evaluation candidates who satisfied inclusion criteria were enrolled into the study. Test stimulation results determined eligibility for randomization into a stimulation (treatment) or delay (control) group. The stimulation group included 34 patients who underwent implantation and were followed for 6 months. The delay group comprised 42 patients who received standard medical therapy for 6 months and then were offered implantation. The stimulation group completed a therapy evaluation test (on versus off) after 6 months.
At 6 months the number of daily incontinence episodes, severity of episodes and absorbent pads or diapers replaced daily due to incontinence were significantly reduced in the stimulation compared to the delay group (all p<0.0001). Of the 34 stimulation group patients 16 (47%) were completely dry and an additional 10 (29%) demonstrated a greater than 50% reduction in incontinence episodes 6 months after implantation. Efficacy appeared to be sustained for 18 months. During the therapy evaluation test the group returned to baseline levels of incontinence when stimulation was inactivated. Urodynamic testing confirmed that sacral nerve stimulation did not adversely affect voiding function. Complications included implantable pulse generator site pain in 15.9% of the patients, implant site pain in 19.1% and lead migration in 7.0%. Surgical revision was required in 32.5% of patients with implants to resolve a complication. There were no reports of permanent injury or nerve damage.
Sacral nerve stimulation is safe and effective in treating refractory urinary urge incontinence.
进行一项前瞻性随机研究,以评估骶神经刺激治疗难治性急迫性尿失禁的效果。
主要结局变量来自排尿日记。在基线评估后,符合纳入标准的受试者被纳入研究。测试刺激结果决定了随机分为刺激(治疗)组或延迟(对照)组的资格。刺激组包括34例接受植入并随访6个月的患者。延迟组包括42例接受6个月标准药物治疗然后接受植入的患者。刺激组在6个月后完成了治疗评估测试(开启与关闭)。
6个月时,与延迟组相比,刺激组每日尿失禁发作次数、发作严重程度以及因尿失禁每日更换的吸收性护垫或尿布数量均显著减少(均p<0.0001)。在34例刺激组患者中,16例(47%)完全无尿失禁,另外10例(29%)在植入后6个月尿失禁发作次数减少超过50%。疗效似乎持续了18个月。在治疗评估测试中,当刺激关闭时,该组尿失禁水平恢复到基线。尿动力学测试证实骶神经刺激对排尿功能无不良影响。并发症包括15.9%的患者出现植入式脉冲发生器部位疼痛,19.1%出现植入部位疼痛,7.0%出现导线移位。32.5%植入装置的患者需要进行手术翻修以解决并发症。没有永久性损伤或神经损伤的报告。
骶神经刺激治疗难治性急迫性尿失禁安全有效。